In an interview with PharmaShots, Paula Ragan, Ph.D., President, and Chief Executive Officer at X4 Pharmaceuticals shared her views on preliminary efficacy and safety data of Mavorixafor + Ibrutinib in […]readmore
Tags : ibrutinib
Shots: The P-III GLOW study evaluates Imbruvica + Venclexta/Venclyxto (I+V) vs chlorambucil + obinutuzumab (C+O) in 211 patients in a ratio (1:1) aged ≥65yrs. with CLL/SLL The study met its […]readmore
Shots: Janssen to present new data from the fixed-duration cohort of P-II CAPTIVATE study, demonstrating 95% of patients treated with combined Imbruvica + Venetoclax were alive and progression-free @2yrs. with […]readmore
Regulatory
Janssen’s Imbruvica (ibrutinib) Receives European Commission Approval for Chronic Lymphocytic
Shots: The approval is based on P-III iLLUMINATE (PCYC-1130) and P-III iNNOVATE (PCYC-1127) study assessing Imbruvica + obinutuzumab vs chlorambucil + obinutuzumab and Imbruvica + rituximab vs rituximab + PBO […]readmore
Pharma
Regulatory
Janssen’s Imbruvica (ibrutinib) Receives CHMP Positive Recommendation for its Expanded
Shots: The CHMP’s positive opinion for CLL is based on P-III iLLUMINATE (PCYC1130) study assessing Imbruvica + obinutuzumab vs chlorambucil + obinutuzumab in patients with newly diagnosed CLL, resulted in […]readmore
Shots: The combinational approval is based P-III iLLUMANTE (PCYC-1130) study results assessing Imbruvica + Gazyva vs chlorambucil + Gazyva in patients with 1L+ Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) aged […]readmore